112.15
Irhythm Holdings Inc stock is traded at $112.15, with a volume of 427.51K.
It is up +2.70% in the last 24 hours and down -5.67% over the past month.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
See More
Previous Close:
$109.20
Open:
$110.81
24h Volume:
427.51K
Relative Volume:
0.77
Market Cap:
$3.69B
Revenue:
$787.85M
Net Income/Loss:
$-27.78M
P/E Ratio:
-129.26
EPS:
-0.8676
Net Cash Flow:
$18.75M
1W Performance:
+0.70%
1M Performance:
-5.67%
6M Performance:
-28.37%
1Y Performance:
-16.42%
Irhythm Holdings Inc Stock (IRTC) Company Profile
Name
Irhythm Holdings Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Compare IRTC vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IRTC
Irhythm Holdings Inc
|
112.15 | 3.59B | 787.85M | -27.78M | 18.75M | -0.8676 |
|
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Irhythm Holdings Inc Stock (IRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-23-25 | Initiated | Evercore ISI | In-line |
| Aug-20-25 | Initiated | BofA Securities | Buy |
| May-02-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-24 | Resumed | Wells Fargo | Equal Weight |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Jun-20-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Feb-07-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Feb-24-22 | Upgrade | Needham | Hold → Buy |
| Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-21-21 | Resumed | Canaccord Genuity | Buy |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
| Jan-29-21 | Reiterated | Needham | Hold |
| Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-11-20 | Initiated | Needham | Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
| Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-10-20 | Initiated | William Blair | Outperform |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
| Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
| Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
| Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
| Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Holdings Inc Stock (IRTC) Latest News
IRhythm Holdings, Inc. (IRTC) Stock Analysis: Exploring A 62% Upside Potential - DirectorsTalk Interviews
iRhythm Holdings, Inc. Revenue Breakdown – MUN:I25 - TradingView
iRhythm Technologies Inc (IRTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
iRhythm Technologies Inc (IRTC) Institutional Confidence - TradingKey
IRTC Initiates Coverage On iRhythm Holdings -- Rating Overweight - GuruFocus
Stephens Initiates iRhythm Technologies at Overweight With $160 Price Target - marketscreener.com
IRTC5766242 Bond Coupon Profile — Rate & Payments - TradingView
IRTC5766242 Bond Profile — Key Metrics - TradingView
IRTC6025550 Bond Profile — Key Metrics - TradingView
ETFs Investing in iRhythm Holdings, Inc. Stocks - TradingView
symbol__ Stock Quote Price and Forecast - CNN
IRTC Q1 2026 Earnings: Surprise EPS Beat Drives Modest Share Gains Despite Revenue UncertaintyTangible Book Value - dars.gov.et
iRhythm Holdings to report Q2 2026 results on Aug 6 - scanx.trade
iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
IRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026 - marketscreener.com
iRhythm’s Q2 Results Call Will Be Live After Aug. 6 Close - Stock Titan
IRTC Maintained by Truist Securities -- Price Target Lowered to $160 - GuruFocus
Truist Adjusts Price Target on iRhythm Technologies to $160 From $174, Maintains Buy Rating - marketscreener.com
Truist Adjusts Price Target on IRhythm Technologies to $160 From $174, Maintains Buy Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Merck & Company (MRK) and Viking Therapeutics (VKTX) - The Globe and Mail
BTIG Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $185 - Moomoo
iRhythm (IRTC) Removed from Conviction List but Rating Remains P - GuruFocus
IRhythm Holdings, Inc. (IRTC): Investor Outlook Reveals 53% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Tax-related share sale by iRhythm (IRTC) EVP after RSU vesting - Stock Titan
iRhythm (IRTC) chief medical officer sells 1,423 shares for RSU tax withholding - Stock Titan
IRhythm Holdings, Inc. (IRTC) Stock Analysis: A 41% Potential Upside Beckons Investors - DirectorsTalk Interviews
Evercore ISI maintains Outperform on iRhythm, cuts target to $150 - scanx.trade
Does iRhythm (IRTC) Balancing a Revenue Beat With In-Line Guidance Recast Its AI Cardiac Story? - Sahm
iRhythm Holdings, Inc. (IRTC) reports Q1 loss, tops revenue estimates - MSN
Q1 Earnings Roundup: iRhythm (NASDAQ:IRTC) And The Rest Of The Patient Monitoring Segment - Yahoo Finance
iRhythm (IRTC) Q1 2026 Earnings: EPS Beats Expectations by 47% Despite Continued LossPost-Earnings Drift - dars.gov.et
IRhythm Holdings, Inc. (IRTC) Stock Analysis: Unveiling A Promising 50% Upside Potential - DirectorsTalk Interviews
Why iRhythm Holdings (IRTC) Is Up 10.8% After Strong Results and New DOJ InquiryAnd What's Next - Sahm
Enterprise value to EBITDA forward of iRhythm Holdings, Inc. – NASDAQ:IRTC - TradingView
I25 Forecast — Price Target — Prediction for 2027 - TradingView
iRhythm Holdings, Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Q1 2026 iRhythm Holdings, Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of iRhythm Holdings, Inc. – NASDAQ:IRTC - TradingView
IRTC Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of iRhythm Holdings, Inc. – NASDAQ:IRTC - TradingView
Price to book forward of iRhythm Holdings, Inc. – NASDAQ:IRTC - TradingView
Price to sales forward of iRhythm Holdings, Inc. – DUS:I25 - TradingView
Price to earnings forward of iRhythm Holdings, Inc. – DUS:I25 - TradingView
iRhythm Holdings, Inc. Actuals & Estimates (NASDAQ:IRTC) - TradingView
iRhythm Holdings (IRTC) Dropped Despite Posting Beat-And-Raise Results - Yahoo Finance
IRTC Reiterated by BTIG -- Price Target Maintained at $185 - GuruFocus
iRhythm Holdings, Inc. (IRTC) Stock Analysis: Unveiling a 70.98% Potential Upside for Astute Investors - DirectorsTalk Interviews
BTIG reiterates Buy on iRhythm, maintains $185 price target - scanx.trade
Top 3 health care stocks you'll regret missing in Q2 - MSN
iRhythm Holdings (IRTC) Advances on Positive Momentum: Key Levels to WatchMonthly Profile - dars.gov.et
Heart Monitoring Device Manufacturer Discloses Cyberattack; Data Breach - The HIPAA Journal
Irhythm Holdings Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):